Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer

BACKGROUND: Acquired resistance development is a major challenge in the epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR–TKI) treatment of non–small cell lung cancer (NSCLC). Here, we investigated the potential effects of the concurrent use of anlotinib and EGFR‐TKI to overcome acqui...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chen, Cao, Honggang, Cui, Yanan, Jin, Shidai, Gao, Wen, Huang, Chenjun, Guo, Renhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487816/
https://www.ncbi.nlm.nih.gov/pubmed/34510760
http://dx.doi.org/10.1111/1759-7714.14141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487816/
https://www.ncbi.nlm.nih.gov/pubmed/34510760
http://dx.doi.org/10.1111/1759-7714.14141

Ejemplares similares